Climb Bio Share Holder Equity 2021-2024 | CLYM

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Climb Bio share holder equity from 2021 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Climb Bio share holder equity from 2021 to 2024. Share holder equity can be defined as the sum of preferred and common equity items

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$174.4B
Vertex Pharmaceuticals (VRTX)	$125.1B
Regeneron Pharmaceuticals (REGN)	$111.8B
Bristol Myers Squibb (BMY)	$106.8B
Gilead Sciences (GILD)	$105.9B
CSL (CSLLY)	$97.5B
GSK (GSK)	$81.1B
Alnylam Pharmaceuticals (ALNY)	$36.4B
Argenex SE (ARGX)	$32.5B
BioNTech SE (BNTX)	$28.6B
Biogen (BIIB)	$27.9B
Illumina (ILMN)	$23.7B
Moderna (MRNA)	$22.2B
BeiGene (BGNE)	$22.1B
Genmab (GMAB)	$15.7B
BioMarin Pharmaceutical (BMRN)	$13.3B
Exact Sciences (EXAS)	$13.1B
Insmed (INSM)	$12.9B
Vaxcyte (PCVX)	$12.6B
Incyte (INCY)	$12.6B
Sarepta Therapeutics (SRPT)	$11.9B
Bio-Techne Corp (TECH)	$11.7B
QIAGEN (QGEN)	$10.1B
Bio-Rad Laboratories (BIO.B)	$9.3B
Legend Biotech (LEGN)	$9.1B
Roivant Sciences (ROIV)	$8.8B
Revolution Medicines (RVMD)	$8.2B
Repligen (RGEN)	$8B
Intra-Cellular Therapies (ITCI)	$7.8B
Ascendis Pharma (ASND)	$7.8B